Journal article icon

Journal article

Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics

Abstract:

Inhibition of sclerostin is a therapeutic approach to lowering fracture risk in patients with osteoporosis. However, data from phase 3 randomized controlled trials (RCTs) of romosozumab, a first-in-class monoclonal antibody that inhibits sclerostin, suggest an imbalance of serious cardiovascular events, and regulatory agencies have issued marketing authorizations with warnings of cardiovascular disease. Here, we meta-analyze published and unpublished cardiovascular outcome trial data of romos...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Subgroup:
Big Data Institute
Role:
Author
ORCID:
0000-0001-7436-4446
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Subgroup:
Big Data Institute
Role:
Author
ORCID:
0000-0001-6625-6074
Expand authors...
Publisher:
American Association for the Advancement of Science Publisher's website
Journal:
Science Translational Medicine Journal website
Volume:
12
Issue:
549
Article number:
eaay6570
Publication date:
2020-06-24
Acceptance date:
2020-05-26
DOI:
EISSN:
1946-6242
ISSN:
1946-6234
Pubs id:
1112307
Local pid:
pubs:1112307
Language:
English
Keywords:

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP